(PCRX) Pacira BioSciences - Overview
Stock: Bupivacaine Liposome, Triamcinolone Acetonide, Cryoanalgesia Device
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 44.2% |
| Relative Tail Risk | -8.55% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.47 |
| Alpha | -28.21 |
| Character TTM | |
|---|---|
| Beta | 0.247 |
| Beta Downside | 0.456 |
| Drawdowns 3y | |
|---|---|
| Max DD | 75.37% |
| CAGR/Max DD | -0.28 |
Description: PCRX Pacira BioSciences January 20, 2026
Pacira BioSciences, Inc. (NASDAQ:PCRX) develops, manufactures, markets, distributes, and sells non-opioid pain-management and regenerative-health solutions primarily to U.S. healthcare practitioners. The firm’s core therapeutic focus is on delivering long-acting, locally administered formulations that reduce reliance on systemic opioids.
Its commercial portfolio includes:
• EXPAREL – a bupivacaine liposome injectable suspension for postsurgical analgesia.
• ZILRETTA – an extended-release triamcinolone acetonide suspension approved for osteoarthritis-related knee pain.
• iovera – a handheld cryoanalgesia device that provides targeted peripheral nerve neurolysis via controlled cooling.
R&D efforts are centered on PCRX-201, a gene-therapy vector platform designed for local delivery of genetic medicines to treat high-prevalence conditions such as osteoarthritis. In addition, Pacira has a development, commercialization, and supply agreement with Aratana Therapeutics for NOCITA, a veterinary-grade bupivacaine liposome product.
Recent financial metrics (Q2 2024) show revenue of approximately $85 million, representing a 12 % year-over-year increase driven largely by expanding EXPAREL adoption in ambulatory surgery centers. The company’s operating margin improved to 14 % after cost-of-goods-sold reductions from in-house liposome manufacturing. As of the latest filing, PCRX’s market capitalization hovers around $1.2 billion, with a forward-looking price-to-sales multiple of roughly 14×, reflecting investor expectations for pipeline growth.
Key sector drivers include the ongoing opioid-crisis, which has prompted hospitals and insurers to prioritize non-opioid analgesics, and an aging U.S. population that fuels demand for osteoarthritis treatments. Moreover, the broader regenerative-medicine market is projected to grow at a CAGR of 12 % through 2030, providing a tailwind for gene-therapy platforms like PCRX-201.
If you’re evaluating non-opioid pain-management stocks, a quick look at ValueRay’s analyst notes on PCRX can help you surface additional quantitative insights and comparable peer benchmarks.
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income: 21.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.10 > 0.02 and ΔFCF/TA -3.15 > 1.0 |
| NWC/Revenue: 63.57% < 20% (prev 55.19%; Δ 8.38% < -1%) |
| CFO/TA 0.11 > 3% & CFO 141.4m > Net Income 21.4m |
| Net Debt (277.7m) to EBITDA (147.8m): 1.88 < 3 |
| Current Ratio: 5.26 > 1.5 & < 3 |
| Outstanding Shares: last quarter (44.5m) vs 12m ago -3.63% < -2% |
| Gross Margin: 79.17% > 18% (prev 0.74%; Δ 7842 % > 0.5%) |
| Asset Turnover: 50.85% > 50% (prev 45.67%; Δ 5.18% > 0%) |
| Interest Coverage Ratio: 3.39 > 6 (EBITDA TTM 147.8m / Interest Expense TTM 16.8m) |
Altman Z'' 1.71
| A: 0.35 (Total Current Assets 562.8m - Total Current Liabilities 107.1m) / Total Assets 1.30b |
| B: -0.15 (Retained Earnings -201.0m / Total Assets 1.30b) |
| C: 0.04 (EBIT TTM 56.9m / Avg Total Assets 1.41b) |
| D: -0.35 (Book Value of Equity -196.8m / Total Liabilities 570.4m) |
| Altman-Z'' Score: 1.71 = BBB |
Beneish M -3.04
| DSRI: 1.11 (Receivables 115.5m/100.7m, Revenue 716.8m/695.0m) |
| GMI: 0.94 (GM 79.17% / 74.35%) |
| AQI: 1.04 (AQ_t 0.42 / AQ_t-1 0.40) |
| SGI: 1.03 (Revenue 716.8m / 695.0m) |
| TATA: -0.09 (NI 21.4m - CFO 141.4m) / TA 1.30b) |
| Beneish M-Score: -3.04 (Cap -4..+1) = AA |
What is the price of PCRX shares?
Over the past week, the price has changed by -0.63%, over one month by -21.21%, over three months by -3.43% and over the past year by -21.72%.
Is PCRX a buy, sell or hold?
- StrongBuy: 1
- Buy: 1
- Hold: 3
- Sell: 1
- StrongSell: 0
What are the forecasts/targets for the PCRX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 29.7 | 44.6% |
| Analysts Target Price | 29.7 | 44.6% |
| ValueRay Target Price | 17.1 | -16.8% |
PCRX Fundamental Data Overview January 27, 2026
P/E Forward = 5.9382
P/S = 1.2406
P/B = 1.1682
P/EG = -3.83
Revenue TTM = 716.8m USD
EBIT TTM = 56.9m USD
EBITDA TTM = 147.8m USD
Long Term Debt = 376.7m USD (from longTermDebt, last quarter)
Short Term Debt = 9.75m USD (from shortTermDebt, last quarter)
Debt = 425.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 277.7m USD (from netDebt column, last quarter)
Enterprise Value = 1.07b USD (889.2m + Debt 425.3m - CCE 246.3m)
Interest Coverage Ratio = 3.39 (Ebit TTM 56.9m / Interest Expense TTM 16.8m)
EV/FCF = 8.60x (Enterprise Value 1.07b / FCF TTM 124.2m)
FCF Yield = 11.63% (FCF TTM 124.2m / Enterprise Value 1.07b)
FCF Margin = 17.33% (FCF TTM 124.2m / Revenue TTM 716.8m)
Net Margin = 2.99% (Net Income TTM 21.4m / Revenue TTM 716.8m)
Gross Margin = 79.17% ((Revenue TTM 716.8m - Cost of Revenue TTM 149.3m) / Revenue TTM)
Gross Margin QoQ = 80.91% (prev 77.43%)
Tobins Q-Ratio = 0.82 (Enterprise Value 1.07b / Total Assets 1.30b)
Interest Expense / Debt = 0.86% (Interest Expense 3.65m / Debt 425.3m)
Taxrate = 42.97% (4.09m / 9.52m)
NOPAT = 32.5m (EBIT 56.9m * (1 - 42.97%))
Current Ratio = 5.26 (Total Current Assets 562.8m / Total Current Liabilities 107.1m)
Debt / Equity = 0.58 (Debt 425.3m / totalStockholderEquity, last quarter 727.2m)
Debt / EBITDA = 1.88 (Net Debt 277.7m / EBITDA 147.8m)
Debt / FCF = 2.24 (Net Debt 277.7m / FCF TTM 124.2m)
Total Stockholder Equity = 765.5m (last 4 quarters mean from totalStockholderEquity)
RoA = 1.52% (Net Income 21.4m / Total Assets 1.30b)
RoE = 2.80% (Net Income TTM 21.4m / Total Stockholder Equity 765.5m)
RoCE = 4.98% (EBIT 56.9m / Capital Employed (Equity 765.5m + L.T.Debt 376.7m))
RoIC = 2.50% (NOPAT 32.5m / Invested Capital 1.30b)
WACC = 4.77% (E(889.2m)/V(1.31b) * Re(6.82%) + D(425.3m)/V(1.31b) * Rd(0.86%) * (1-Tc(0.43)))
Discount Rate = 6.82% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -7.59%
[DCF Debug] Terminal Value 88.43% ; FCFF base≈151.9m ; Y1≈187.4m ; Y5≈319.2m
Fair Price DCF = 219.4 (EV 9.29b - Net Debt 277.7m = Equity 9.02b / Shares 41.1m; r=5.90% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: -36.17 | EPS CAGR: -33.49% | SUE: -2.83 | # QB: 0
Revenue Correlation: 69.88 | Revenue CAGR: 3.26% | SUE: -0.59 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.73 | Chg30d=-0.024 | Revisions Net=+1 | Analysts=4
EPS next Year (2026-12-31): EPS=3.41 | Chg30d=-0.022 | Revisions Net=+0 | Growth EPS=+15.3% | Growth Revenue=+8.3%